Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Gastroenterology Product Name: APT-1011
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Ellodi Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NLS Pharmaceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2020